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TREATMENT	WITH	LEVOTHYROXINE	DOES	NOT	NORMALIZE	SERUM	CHOLESTEROL	IN	HYPOTHYROID	PATIENTS	
	
Hypothyroidism	is	the	second	most	common	endocrine	disease	affecting	approximately	5%	of	
the	population,	particularly	females	and	older	adults	(1).	Fortunately,	the	diagnosis	and	treat-
ment	are	straightforward	for	the	majority	of	patients.	Both	rely	on	measuring	serum	levels	of	
thyrotropin	 (TSH),	 the	pituitary	hormone	 that	 fluctuates	according	 to	 the	circulating	 levels	of	
thyroid	hormones	-	thyroxine	(T4)	and	its	biologically	active	metabolite,	triiodothyronine	(T3).	
High	serum	TSH	levels	indicate	that	the	thyroid	secretion	is	insufficient,	establishing	the	diagno-
sis	 of	 primary	 hypothyroidism.	 Standard	 treatment	 is	 with	 levothyroxine	 (LT4),	 the	 dose	 of	
which	is	adjusted	until	serum	TSH	levels	have	returned	to	the	normal	reference	range.	At	this	
point	most	patients	are	asymptomatic	and	clinically	euthyroid	(2).	However,	mounting	evidence	
indicates	that	normalization	of	TSH	 levels	might	not	reflect	regularization	of	all	T3-dependent	
biological	effects	or	that	all	signs	and	symptoms	of	hypothyroidism	are	eliminated	(3).	This	is	an	
important	 concept	 as	 quantifying	 the	 descrepency	 between	 tissue	 thyroid	 status	 and	 serum	
TSH	is	key	to	the	management	of	hypothyroidism	.		
	
Recent	studies	have	revealed	that	the	liver	might	have	diminished	T3	signaling	in	euthyroid	in-
dividuals	on	LT4	as	total-	and	LDL-cholesterol	levels	remain	higher	in	LT4-treated	patients	with	
normal	serum	TSH.	In	keeping	with	this	LT4	treated	patients	have	a	higher	utilization	of	statins	
(3-5).	This	new	 information	should	alert	physicians	 to	closely	monitor	 the	 lipid	profile	of	LT4-
treated	patients	as	they	are	at	increased	risk	of	developing	hypercholesterolemia,	despite	hav-
ing	normal	serum	TSH	levels.	
	
Preclinical	studies	of	LT4-treated	thyroidectomized	rats	indicate	that	plasma	and	tissue	T3	lev-
els	are	not	normalized	despite	normal	serum	TSH	levels	(6).	This	is	associated	with	reduced	T3-
signaling	in	the	liver,	skeletal	muscle	and	brain	(7).	In	LT4-treated	patients,	there	is	strong	ob-
jective	evidence	that	the	 liver	might	remain	hypothyroid.	The	 lipid	profile	of	26	female	and	3	
male	euthyroid	patients	 studied	before	and	one	year	after	 total	 thyroidectomy	 revealed	 that	
while	on	LT4	therapy	patients	exhibited	an	increase	in	serum	LDL-cholesterol	levels	of	6	mg/dl,	
despite	normalization	of	 serum	TSH	 (5).	A	 similar	 study	of	 1,092	 LT4-treated	 female	patients	
also	revealed	elevation	of	about	15	mg/dl	in	total	cholesterol	levels	two	years	after	surgery	(4).	
In	 fact,	 a	 meta-analysis	 of	 65	 studies	 that	 compared	 1,878	 LT4-treated	 patients	 to	 14,493	
healthy	 controls	 revealed	 that	 both	 total-cholesterol	 and	 LDL-cholesterol	 remain	 elevated	 by	
9.6	and	3.3	mg/dl,	respectively,	after	serum	TSH	has	been	normalized	(8).	In	fact,	NHANES	data	
on	360	female	and	109	male	patients	on	LT4	as	compared	to	controls	matched	for	age,	sex	and	
ethnic	background,	revealed	that	patients	on	LT4	are	54%	more	likely	to	be	on	statins	(3).		
	
There	 is	 general	 consensus	 that	 T3	 acts	by	modifying	 the	expression	of	 gene	 sets	 in	 virtually	
every	cell.	A	reduction	in	T3	signaling	modifies	the	expression	of	gene	sets	that	are	sensitive	to	
T3,	explaining	the	signs	and	symptoms	of	hypothyroidism.	T3	signaling	in	the	liver	sets	the	bal-
ance	between	cholesterol	and	bile	acid	syntheses.	A	 reduction	 in	T3	signaling	elevates	serum	
cholesterol	 levels	by	 slowing	down	 the	expression	of	Cyp7A,	 the	 key	enzyme	 in	 the	pathway	
that	converts	cholesterol	to	bile	acids.	Therefore,	the	fact	that	total	cholesterol	homeostasis	is	
not	restored	in	LT4-treated	patients	is	a	strong	indication	that	T3-signaling	in	the	liver	remains	
abnormally	low,	despite	normalization	of	serum	TSH	levels.		
	
As	 in	many	 tissues,	T3	signaling	 in	 the	 liver	 is	defined	by	 the	 levels	of	circulating	T3.	There	 is	
general	understanding	 that	 in	 LT4-treated	patients	 two	deiodinase	pathways,	D1	and	D2,	de-
iodinate	T4	and	to	produce	T3,	fully	restoring	circulating	and	tissue	T3	levels	(9).	However,	evi-
dence	that	this	is	not	the	case	has	been	available	since	the	early	70s	(10).	Despite	subsequent	
smaller	studies	suggesting	otherwise	(11,12),	in	a	cross-sectional	study	of	1,811	LT4-treated	hy-
pothyroid	patients	with	normal	serum	TSH,	serum	T3	was	found	to	be	17%	lower	when	com-
pared	to	3,875	control	individuals;	in	15.2%	of	the	patients,	serum	T3	is	below	the	normal	range	
(13).	Similar	findings	were	obtained	in	135	consecutive	patients	who	underwent	total	thyroid-
ectomy	 (14),	and	 through	 the	analyzes	of	publicly	available	NHANES	data	on	469	LT4-treated	
patients	(3).		
	
It	is	notable	that	in	some	of	these	studies,	normalization	of	serum	cholesterol	was	achieved	by	
increasing	the	dose	of	LT4	(4,5),	a	change	that	also	normalizes	serum	T3	but	results	in	lowering	
serum	TSH	below	the	normal	reference	range.	Future	clinical	trials	will	be	necessary	to	deter-
mine	whether	the	long-term	benefits	of	restoring	cholesterol	homeostasis	outweighs	the	risks	
of	keeping	a	serum	TSH	below	normal	range.	An	alternative	possibility	is	to	place	hypothyroid	
patients	on	combination	therapy,	what	results	 in	slightly	higher	serum	T3.	However,	this	regi-
men	is	controversial	and	has	not	been	accepted	for	routine	treatment	of	hypothyroidism	(2).		
	
It	is	also	important	to	recognize	that	the	slightly	lower	serum	T3	levels	observed	in	LT4-treated	
patients	cannot	be	categorized	as	subclinical	hypothyroidism.	The	latter	is	a	condition	in	which	
patients	exhibit	mildly	elevated	 serum	TSH	while	keeping	 	 serum	T4	and	T3	 levels	within	 the	
population	 reference	 range.	Whereas	 such	patients	do	exhibit	 alterations	 in	 lipid	profile,	 it	 is	
not	clear	that	treatment	with	LT4	results	in	measurable	benefits	.	Indeed,	it	is	only	in	the	more	
severe	end	of	SCH	that	clear	benefits	of	correcting	SCH	with	regard	to	cardiovascular	risk	fac-
tors	are	seen	and	only	in	younger	and	middle-aged	individuals	(15).			Persistent	subclinical	hy-
pothyroidism	due	to	ongoing	thyroid	inflammation	or	other	intrinsic	thyroid	disease,	will	result	
in	preservation	of	T3	levels	and	T3:T4	ratio	which	is	not	observed	in	individuals	on	LT4.	
 
	
Conclusion:		
This	summary	highlights	that	whilst	abnormal	lipid	profiles	and	hypothyroidism	often	promote	
screening	for	the	other	condition,	it	is	important	to	realise	that	individuals	on	LT4	are	also	at	
increased	risk	of	developing	hyperlipidemia.	Therefore	the	screening	for	an	abnormal	lipid	pro-
file	should	continue	in	hypothyroid	individuals	even	after	normalization	of	TSH.	This	summary	
also	raises	a	broader	issue;	lipid	metabolism	is	something	which	we	can	readily	measure	with	
simple	blood	tests	it	is	easy	to	identify	as	a	problem.	The	effects	of	lower	T3	availability	and	
subsequent	gene	expression	in	other	tissues	such	as	the	brain,	may	affect	outcomes	such	as	
fatigue	and	mood	which	are	less	easily	measured	but	of	perhaps	greater	importance	to	the	pa-
tient.														
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